Introduction: Eosinophilic oesophagitis (EoE) is a chronic immune-antigen-mediated inflammatory disease characterized by symptoms of oesophageal dysfunction and histologically by eosinophil-predominant infiltration of the oesophageal squamous epithelium. Diagnosis and monitoring of disease activity and treatment response currently rely on endoscopic and histological assessments, imposing a considerable burden, particularly on paediatric patients. To date, no validated non-invasive biomarkers have been established for the diagnosis of EoE or the assessment of disease activity. Aims: The primary aim of this study was to identify urinary metabolomic biomarkers distinguishing EoE from other oesophageal disorders in children presenting with upper gastrointestinal symptoms. Secondary aims were to identify metabolomic biomarkers or dysregulated metabolic pathways distinguishing: (1) active EoE (newly diagnosed, relapsed after treatment discontinuation, or persistent despite ongoing therapy) from remission; (2) histological remission from relapse in children receiving treatment, irrespective of the therapeutic regimen; and (3) histological remission from relapse specifically in children receiving topical corticosteroid therapy. Materials and methods: We conducted an observational, longitudinal, prospective study between March 2018 and April 2021. Paediatric patients undergoing upper gastrointestinal (GI) endoscopy during the study period were enrolled in the study. Subjects were divided into two groups: the EoE group including subjects with new or previous diagnosis of EoE and a control group other oeosphageal disorders. Urine samples were collected with a standardised procedure prior to endoscopy and analysed using untargeted liquid chromatography–mass spectrometry (LC-MS). Metabolomic profiles compared EoE and controls as first aim and compared disease activity and ongoing treatment as secondary aims. Results: The study population comprised 99 patients, including 72 children in the EoE group (59 males; median age: 12 years; median body weight: 45.4 kg) and 27 children in the control group (14 males; median age: 13 years; median body weight: 44.5 kg). Multivariate statistical analysis identified a model capable of discriminating between patients with EoE and those with non-EoE oesophageal disorders. Among the metabolites identified, tetrahydro-11-dehydrocorticosterone-H₂O emerged as a metabolite with biological plausibility, higher in non-EoE oesophageal conditions. This finding may be consistent with differences in the inflammatory profiles of the two conditions, including the absence of the characteristic (Th2)-mediated inflammation of EoE in GERD and functional dysphagia. Similarly, PLS analysis identified a robust model capable of distinguishing between patients with active disease and those in remission during treatment. Among the metabolites identified, 1,7-dimethyluric acid was significantly associated with EoE remission. Conclusions: Untargeted metabolomic analysis identified models able to discriminate children with EoE from those with other oesophageal disorders and, among treated patients, to distinguish active disease from remission. Tetrahydro-11-dehydrocorticosterone-H₂O was significantly reduced in children with EoE compared with those with other oesophageal disorders, and 1,7-dimethyluric acid was associated with EoE remission during treatment. These preliminary findings suggest that urinary metabolomics may represent a promising non-invasive approach to support disease monitoring in pediatric EoE. Further studies in larger cohorts are needed to validate these candidate biomarkers and assess their clinical utility.

Introduction: Eosinophilic oesophagitis (EoE) is a chronic immune-antigen-mediated inflammatory disease characterized by symptoms of oesophageal dysfunction and histologically by eosinophil-predominant infiltration of the oesophageal squamous epithelium. Diagnosis and monitoring of disease activity and treatment response currently rely on endoscopic and histological assessments, imposing a considerable burden, particularly on paediatric patients. To date, no validated non-invasive biomarkers have been established for the diagnosis of EoE or the assessment of disease activity. Aims: The primary aim of this study was to identify urinary metabolomic biomarkers distinguishing EoE from other oesophageal disorders in children presenting with upper gastrointestinal symptoms. Secondary aims were to identify metabolomic biomarkers or dysregulated metabolic pathways distinguishing: (1) active EoE (newly diagnosed, relapsed after treatment discontinuation, or persistent despite ongoing therapy) from remission; (2) histological remission from relapse in children receiving treatment, irrespective of the therapeutic regimen; and (3) histological remission from relapse specifically in children receiving topical corticosteroid therapy. Materials and methods: We conducted an observational, longitudinal, prospective study between March 2018 and April 2021. Paediatric patients undergoing upper gastrointestinal (GI) endoscopy during the study period were enrolled in the study. Subjects were divided into two groups: the EoE group including subjects with new or previous diagnosis of EoE and a control group other oeosphageal disorders. Urine samples were collected with a standardised procedure prior to endoscopy and analysed using untargeted liquid chromatography–mass spectrometry (LC-MS). Metabolomic profiles compared EoE and controls as first aim and compared disease activity and ongoing treatment as secondary aims. Results: The study population comprised 99 patients, including 72 children in the EoE group (59 males; median age: 12 years; median body weight: 45.4 kg) and 27 children in the control group (14 males; median age: 13 years; median body weight: 44.5 kg). Multivariate statistical analysis identified a model capable of discriminating between patients with EoE and those with non-EoE oesophageal disorders. Among the metabolites identified, tetrahydro-11-dehydrocorticosterone-H₂O emerged as a metabolite with biological plausibility, higher in non-EoE oesophageal conditions. This finding may be consistent with differences in the inflammatory profiles of the two conditions, including the absence of the characteristic (Th2)-mediated inflammation of EoE in GERD and functional dysphagia. Similarly, PLS analysis identified a robust model capable of distinguishing between patients with active disease and those in remission during treatment. Among the metabolites identified, 1,7-dimethyluric acid was significantly associated with EoE remission. Conclusions: Untargeted metabolomic analysis identified models able to discriminate children with EoE from those with other oesophageal disorders and, among treated patients, to distinguish active disease from remission. Tetrahydro-11-dehydrocorticosterone-H₂O was significantly reduced in children with EoE compared with those with other oesophageal disorders, and 1,7-dimethyluric acid was associated with EoE remission during treatment. These preliminary findings suggest that urinary metabolomics may represent a promising non-invasive approach to support disease monitoring in pediatric EoE. Further studies in larger cohorts are needed to validate these candidate biomarkers and assess their clinical utility.

Urinary Metabolomics in the Characterization of Paediatric Eosinophilic Oesophagitis

GIACOBBO, VITTORIA
2024/2025

Abstract

Introduction: Eosinophilic oesophagitis (EoE) is a chronic immune-antigen-mediated inflammatory disease characterized by symptoms of oesophageal dysfunction and histologically by eosinophil-predominant infiltration of the oesophageal squamous epithelium. Diagnosis and monitoring of disease activity and treatment response currently rely on endoscopic and histological assessments, imposing a considerable burden, particularly on paediatric patients. To date, no validated non-invasive biomarkers have been established for the diagnosis of EoE or the assessment of disease activity. Aims: The primary aim of this study was to identify urinary metabolomic biomarkers distinguishing EoE from other oesophageal disorders in children presenting with upper gastrointestinal symptoms. Secondary aims were to identify metabolomic biomarkers or dysregulated metabolic pathways distinguishing: (1) active EoE (newly diagnosed, relapsed after treatment discontinuation, or persistent despite ongoing therapy) from remission; (2) histological remission from relapse in children receiving treatment, irrespective of the therapeutic regimen; and (3) histological remission from relapse specifically in children receiving topical corticosteroid therapy. Materials and methods: We conducted an observational, longitudinal, prospective study between March 2018 and April 2021. Paediatric patients undergoing upper gastrointestinal (GI) endoscopy during the study period were enrolled in the study. Subjects were divided into two groups: the EoE group including subjects with new or previous diagnosis of EoE and a control group other oeosphageal disorders. Urine samples were collected with a standardised procedure prior to endoscopy and analysed using untargeted liquid chromatography–mass spectrometry (LC-MS). Metabolomic profiles compared EoE and controls as first aim and compared disease activity and ongoing treatment as secondary aims. Results: The study population comprised 99 patients, including 72 children in the EoE group (59 males; median age: 12 years; median body weight: 45.4 kg) and 27 children in the control group (14 males; median age: 13 years; median body weight: 44.5 kg). Multivariate statistical analysis identified a model capable of discriminating between patients with EoE and those with non-EoE oesophageal disorders. Among the metabolites identified, tetrahydro-11-dehydrocorticosterone-H₂O emerged as a metabolite with biological plausibility, higher in non-EoE oesophageal conditions. This finding may be consistent with differences in the inflammatory profiles of the two conditions, including the absence of the characteristic (Th2)-mediated inflammation of EoE in GERD and functional dysphagia. Similarly, PLS analysis identified a robust model capable of distinguishing between patients with active disease and those in remission during treatment. Among the metabolites identified, 1,7-dimethyluric acid was significantly associated with EoE remission. Conclusions: Untargeted metabolomic analysis identified models able to discriminate children with EoE from those with other oesophageal disorders and, among treated patients, to distinguish active disease from remission. Tetrahydro-11-dehydrocorticosterone-H₂O was significantly reduced in children with EoE compared with those with other oesophageal disorders, and 1,7-dimethyluric acid was associated with EoE remission during treatment. These preliminary findings suggest that urinary metabolomics may represent a promising non-invasive approach to support disease monitoring in pediatric EoE. Further studies in larger cohorts are needed to validate these candidate biomarkers and assess their clinical utility.
2024
Urinary Metabolomics in the Characterization of Paediatric Eosinophilic Oesophagitis
Introduction: Eosinophilic oesophagitis (EoE) is a chronic immune-antigen-mediated inflammatory disease characterized by symptoms of oesophageal dysfunction and histologically by eosinophil-predominant infiltration of the oesophageal squamous epithelium. Diagnosis and monitoring of disease activity and treatment response currently rely on endoscopic and histological assessments, imposing a considerable burden, particularly on paediatric patients. To date, no validated non-invasive biomarkers have been established for the diagnosis of EoE or the assessment of disease activity. Aims: The primary aim of this study was to identify urinary metabolomic biomarkers distinguishing EoE from other oesophageal disorders in children presenting with upper gastrointestinal symptoms. Secondary aims were to identify metabolomic biomarkers or dysregulated metabolic pathways distinguishing: (1) active EoE (newly diagnosed, relapsed after treatment discontinuation, or persistent despite ongoing therapy) from remission; (2) histological remission from relapse in children receiving treatment, irrespective of the therapeutic regimen; and (3) histological remission from relapse specifically in children receiving topical corticosteroid therapy. Materials and methods: We conducted an observational, longitudinal, prospective study between March 2018 and April 2021. Paediatric patients undergoing upper gastrointestinal (GI) endoscopy during the study period were enrolled in the study. Subjects were divided into two groups: the EoE group including subjects with new or previous diagnosis of EoE and a control group other oeosphageal disorders. Urine samples were collected with a standardised procedure prior to endoscopy and analysed using untargeted liquid chromatography–mass spectrometry (LC-MS). Metabolomic profiles compared EoE and controls as first aim and compared disease activity and ongoing treatment as secondary aims. Results: The study population comprised 99 patients, including 72 children in the EoE group (59 males; median age: 12 years; median body weight: 45.4 kg) and 27 children in the control group (14 males; median age: 13 years; median body weight: 44.5 kg). Multivariate statistical analysis identified a model capable of discriminating between patients with EoE and those with non-EoE oesophageal disorders. Among the metabolites identified, tetrahydro-11-dehydrocorticosterone-H₂O emerged as a metabolite with biological plausibility, higher in non-EoE oesophageal conditions. This finding may be consistent with differences in the inflammatory profiles of the two conditions, including the absence of the characteristic (Th2)-mediated inflammation of EoE in GERD and functional dysphagia. Similarly, PLS analysis identified a robust model capable of distinguishing between patients with active disease and those in remission during treatment. Among the metabolites identified, 1,7-dimethyluric acid was significantly associated with EoE remission. Conclusions: Untargeted metabolomic analysis identified models able to discriminate children with EoE from those with other oesophageal disorders and, among treated patients, to distinguish active disease from remission. Tetrahydro-11-dehydrocorticosterone-H₂O was significantly reduced in children with EoE compared with those with other oesophageal disorders, and 1,7-dimethyluric acid was associated with EoE remission during treatment. These preliminary findings suggest that urinary metabolomics may represent a promising non-invasive approach to support disease monitoring in pediatric EoE. Further studies in larger cohorts are needed to validate these candidate biomarkers and assess their clinical utility.
EoE
metabolomics
paediatric
File in questo prodotto:
File Dimensione Formato  
Giacobbo_Vittoria.pdf

Accesso riservato

Dimensione 1.84 MB
Formato Adobe PDF
1.84 MB Adobe PDF

The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12608/120642